Prothena Corporation plc
Prothena Corporation plc logo
PRTA

Prothena Corporation plc (PRTA)

$27.892.73%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$27.29
Day's Range
$28.27
$21.06
52-Week Range
$79.75
1 month return6.45%
3 month return27.75%
1 year return48.72%
5 year return54.84%

Company Information

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s partnered programs include prasinezumab (PRX002/RG7935), in collaboration with Roche for the potential treatment of Parkinson’s disease and other related synucleinopathies, and programs that target tau (PRX005), TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases. Prothena’s wholly-owned programs include PRX004 for the potential treatment of ATTR amyloidosis, and a portfolio of programs for the potential treatment of Alzheimer’s disease including PRX012 that targets Aß (Amyloid beta).
OrganizationProthena Corporation plc
Employees7
CEOGene Kinney
IndustryHealth Technology

Analyst Recommendation

based on 14 analysts ratings

Buy
85%
Buy
14%
Hold
0%
Sell

Based on 14 Wall street analysts offering stock ratings for Prothena Corporation plc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 158.87%

Current

$27.89

Target

$72.2

Recommendation Trend

Based on 14 analyst

Current1M Ago3M Ago
Buy
12
13
13
Hold
2
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
1.3B
Book Value
9.99
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
1.38
PE Ratio
19.6594
PEG Ratio
0.8
Wall Street Target Price
74.44

Valuation

Trailing PE19.66
Forward PE64.1
Price/Sales (ttm)
6.32
Price/Book (mrq)
3.34
Enterprise Value
991.1M
Enterprise Value/Revenue
4.94
Enterprise Value/Ebitda
12.58

Technicals

Beta
1.3
50 Day MA
35.08
200 Day MA
49.78

Institutional Holdings

EcoR1 Capital, LLC

24.75%

T. Rowe Price Associates, Inc.

13.06%

BlackRock Inc

8.27%

FMR Inc

5.72%

State Street Corporation

5.06%

First Light Asset Management, LLC

3.93%

Discover more

Frequently Asked Questions

What is Prothena Corporation plc share price today?

Can Indians buy Prothena Corporation plc shares?

How can I buy Prothena Corporation plc shares from India?

Can Fractional shares of Prothena Corporation plc be purchased?

What are the documents required to start investing in Prothena Corporation plc stocks?

What are today’s High and Low prices of Prothena Corporation plc?

What are today’s traded volumes of Prothena Corporation plc?

What is today’s market capitalisation of Prothena Corporation plc?

What is the 52 Week High and Low Range of Prothena Corporation plc?

How much percentage Prothena Corporation plc is down from its 52 Week High?

How much percentage Prothena Corporation plc is up from its 52 Week low?

What are the historical returns of Prothena Corporation plc?

Who is the Chief Executive Officer (CEO) of Prothena Corporation plc?